

Date: 10-05-2021.

To,
The Manager
Listing Compliance Department,
BSE Limited (Bombay Stock Exchange Limited),
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.
Script Id "BAJAJHCARE", Script Code "539872".

Dear Sir/Madam,

Ref: Your Email dated May 10, 2021 bearing No. L/SURV/ONL/PV/RS/ 2021-2022/183

Sub: Clarification on price movement.

We refer your email dated May 10, 2021 having reference No: L/SURV/ONL/PV/RS/ 2021-2022 / 183 seeking clarification with respect to significant movement in share price of the Company.

In this connection we would like to inform that, we have been regularly informing all the material events and information that have a bearing on the operation / performance of the Company including all the price sensitive information, as and when required to do so under applicable Regulations and Listing Obligations.

Recently, the Company has launched new products Antiviral Favipiravir Tablets (brand name "Favijaj") which is used for the treatment of mild to moderate Covid-19 diseased and Ivermectin Tablets (brand name "Ivejaj)" an Anti-Parasitic Drug which is used to control parasitic roundworm infections and curing parasitic infections, helps to improve health of Covid-19 Patients and the announcement of the launching was duly intimated to the Stock Exchange as required under regulation 30 of SEBI (LODR) Regulations, 2015 on May 04, 2021 and May 06, 2021 respectively.

Further, we would like to state that none of the promoters/director and/or insider have done any transactions in the shares of the Company and the recent movement in the price of the shares of the Company may purely be due to market forces and condition and the Company and promoters have nothing to do with price movement.

We hope the above is clarified.

For and behalf of Board of Directors of

Bajaj Healthcare Limited

Company Secretary Aakash Keshari